Mol Endocrinol 30:118132
Statements Author contributions PV, JM, GP, and JDR: bibliographic search, writing, review and/or revision of the manuscript
Case reports of KD addressing anxiety describe two cases of decreased anxiety symptoms in a woman with women, one with bipolar I disorder and another with unspecified mood disorder, comorbid emotional dysregulation, body dysmorphic disorder, and eating disorder (36, 37), and one case report that describes the elimination of anxiety symptoms in a man with bipolar disorder (38)
For research purposes, semaglutide is one of the most well-characterized GLP-1 receptor agonists available, with an extensive clinical trial database spanning over 10 years and multiple Phase 3 programs
Corresponding Author Eder Luna-Ceron, M.D., M.Sc Texas Tech University Health Sciences Center, Internal Medicine Department, El Paso, Texas 79905 Email: [email protected]